Protease-Activated Receptors 2-Antagonist Suppresses Asthma by Inhibiting Reactive Oxygen Species-Thymic Stromal Lymphopoietin Inflammation and Epithelial Tight Junction Degradation
Overview
Affiliations
Purpose: Protease-activated receptor 2 (PAR2) reportedly triggers the immune response in allergic asthma. We aimed to investigate the mechanism on allergic inflammation mediated by PAR2.
Methods: Human lung epithelial cells (A549 cells) were used for , and the German cockroach extract (GCE)-induced mouse model was developed for studies.
Results: In A549 cells, the levels of reactive oxygen species (ROS) and thymic stromal lymphopoietin (TSLP) were significantly increased by GCE treatment, but were suppressed by PAR2-antagonist (PAR2-ant) or N-acetylcysteine (NAC) treatment. Claudin-1 was degraded by GCE, and was restored by PAR2-ant or NAC in the cells. In the mouse model, the clinical appearance including bronchial hyperresponsiveness, bronchoalveolar lavage fluid analysis and total immunoglobulin E were significantly suppressed by PAR2-ant or NAC. Moreover, TSLP levels in the lung were suppressed by the same treatments in the lung. Claudin-1 was also degraded by GCE, and was restored by PAR2-ant or NAC.
Conclusions: ROS generation and epidermal tight junction degradation are triggered by protease, followed by the induction of TSLP in allergic asthma. Our findings could suggest that PAR2-ant or anti-oxidants could be considered for allergic diseases as preventive alternatives.
Tang D, Wang C, Liu H, Wu J, Tan L, Liu S Int J Mol Sci. 2024; 25(16).
PMID: 39201796 PMC: 11354367. DOI: 10.3390/ijms25169110.
Par2-mediated responses in inflammation and regeneration: choosing between repair and damage.
Reches G, Piran R Inflamm Regen. 2024; 44(1):26.
PMID: 38816842 PMC: 11138036. DOI: 10.1186/s41232-024-00338-1.
Midgut microbiota affects the intestinal barrier by producing short-chain fatty acids in .
Song M, Zhang Z, Li Y, Xiang Y, Li C Front Microbiol. 2023; 14:1263731.
PMID: 37915855 PMC: 10616862. DOI: 10.3389/fmicb.2023.1263731.
GB83, an Agonist of PAR2 with a Unique Mechanism of Action Distinct from Trypsin and PAR2-AP.
Heo Y, Yang E, Lee Y, Seo Y, Ryu K, Jeon H Int J Mol Sci. 2022; 23(18).
PMID: 36142527 PMC: 9506296. DOI: 10.3390/ijms231810631.
Claudin-1 Mediated Tight Junction Dysfunction as a Contributor to Atopic March.
Xia Y, Cao H, Zheng J, Chen L Front Immunol. 2022; 13:927465.
PMID: 35844593 PMC: 9277052. DOI: 10.3389/fimmu.2022.927465.